Zevra Therapeutics (ZVRA) Insider Trading & Ownership $7.39 +0.13 (+1.79%) (As of 08/29/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Zevra Therapeutics (NASDAQ:ZVRA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.40%Number OfInsiders Buying(Last 12 Months)4Amount OfInsider Buying(Last 12 Months)$199,165.00Number OfInsiders Selling(Last 12 Months)0 Get ZVRA Insider Trade Alerts Want to know when executives and insiders are buying or selling Zevra Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ZVRA Insider Buying and Selling by Quarter Ad Crypto 101 MediaThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing: While traditional investments are floundering, the next big tech wave is charging ahead: Artificial Intelligence.Click here to get details on this opportunity now. Zevra Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/17/2024R. Laduane CliftonCFOBuy2,000$6.77$13,540.00 7/16/2024Thomas AndersonDirectorBuy10,000$6.81$68,100.00 7/12/2024John B BodeDirectorBuy10,000$5.87$58,700.00 9/6/2023R. Laduane CliftonCFOBuy1,000$4.96$4,960.00 9/5/2023John B BodeDirectorBuy10,000$5.13$51,300.00 9/5/2023Joshua SchaferEVPBuy500$5.13$2,565.00 (Data available from 1/1/2013 forward) ZVRA Insider Trading Activity - Frequently Asked Questions Who is on Zevra Therapeutics's Insider Roster? The list of insiders at Zevra Therapeutics includes Corey Michael Watton, John B Bode, Joshua Schafer, Matthew R Plooster, R. Laduane Clifton, Richard W Pascoe, Tamara A Seymour, Thomas Anderson, and Timothy J Sangiovanni. Learn more on insiders at ZVRA. What percentage of Zevra Therapeutics stock is owned by insiders? 2.40% of Zevra Therapeutics stock is owned by insiders. Learn more on ZVRA's insider holdings. Which Zevra Therapeutics insiders have been buying company stock? The following insiders have purchased ZVRA shares in the last 24 months: Corey Michael Watton ($5,474.25), John B Bode ($160,400.00), Joshua Schafer ($17,205.00), Matthew R Plooster ($46,200.00), R. Laduane Clifton ($39,221.75), Richard W Pascoe ($42,000.00), Tamara A Seymour ($2,501.58), Thomas Anderson ($68,100.00), and Timothy J Sangiovanni ($4,968.00). How much insider buying is happening at Zevra Therapeutics? Insiders have purchased a total of 74,684 ZVRA shares in the last 24 months for a total of $386,070.58 bought. More Insider Trading Tools from MarketBeat Related Companies: Gyre Therapeutics Insider Trades Prothena Insider Trades Tyra Biosciences Insider Trades Xencor Insider Trades Cullinan Therapeutics Insider Trades Tarsus Pharmaceuticals Insider Trades Aligos Therapeutics Insider Trades AnaptysBio Insider Trades Evolus Insider Trades Bicycle Therapeutics Insider Trades Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: MGM Insiders Bet Big on Its Undervalued Stock3 Small Cap Stocks Insiders Are Actively BuyingTop 2 High-Yield Stocks That Insiders Are BuyingInsider Selling: When It Matters and When It Doesn'tInsiders Sell These Tech Stocks, but Investors Shouldn’t This page (NASDAQ:ZVRA) was last updated on 8/30/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressHow likely is a Trump victory? Polymarket (the world's largest prediction market) gives Trump a 63% chance ...Colonial Metals | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredExposed: 3 CENT Crypto to Explode August 19th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredPowerful new AI force leaving everyone behindThere’s a powerful new force sweeping through the AI world right now… And if you don’t know what it is… ...Traders Agency | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinThe Bitcoin Halving ignited the 2024 boom, and altcoins are primed to SKYROCKET. Last year we tipped off ou...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.